Gabriela Quintero1,2, Andrea Guzman2, Diana M Gomez2,3, Heliodor Kasprzak2,4, Pedro Penagos2,5, Heber Siachoque2,6, Alexander Shevelev2,7, Annabelle Trojan2,8, Alvaro Alvarez2,8 and Jerzy Trojan2,6,9*
1Faculty of Medicine, UNAB University, Floridablanca, Colombia
2ICGT – International Cancer Gene Therapy, Bogota / Paris, Colombia and France
3Faculty of Science, Dept. Chemistry, UN – National University, Bogota, Colombia
4Faculty of Medicine, UMK – Nicolaus Copernic University, Torun, Poland
5Dept. Neurosurgery, INC – National Cancer Institute, Bogota, Colombia
6CEDEA – Center of Oncologic Diagnostic, Bogota, Colombia
7Laboratory of Cell Engineering, Indust. Res. Complex, Moscow, Russia
8Faculty of Medicine, University of Cartagena, Cartagena de Indias, Colombia
9INSERM U602, Cancer Center, Villejuif, France
*Corresponding Author: Gabriela Quintero, Faculty of Medicine, UNAB, Floridablanca, Colombia and Jerzy Trojan, ICGT – International Cancer Gene Therapy, Bogota / Paris, Colombia and France.
Received: November 05, 2019; Published: December 10, 2019
This review gives an example of current recommended post-surgery treatment of malignant brain tumor – glioblastoma whose prognostic is always fatal. In this striking area of neuro-oncology, despite the use of modern approaches of surgery, radiotherapy, hormonotherapy and especially chemotherapy, the results are still far from our expectations. Two years ago, the government of USA has approved the Moonshot program which recommends the introduction in oncology, as an obligatory challenge, of immunotherapy – the domain based on basic science of molecular biology, genetics and immunology. In this article we have described general ideas and clinical results of cancer gene therapy, being also cancer immunogen therapy, which has showed the promising results as follows. In cancer cells provided from surgical biopsy, the expression of IGF-I, principal growth factor responsible of neoplastic development, was suppressed using anti – gene technology. These genetically modified cancer cells, playing the role of vaccines, while injected subcutaneously in cancer patients, induced an immune anti – response, mediated by lymphocytes CD8. During last twenty-five years, the malignant tumors, principally glioblastoma, were treated using anti - gene IGF-I therapy. The median survival of treated patients has reached 20 months, and in some case 3 and 4 years. (Using classical treatment, including chemotherapy, the median survival is maximum 14 month, rarely 18 months).
Keywords: Cancer Gene Therapy; Glioblastoma; Antisense; Triple Helix; IGF-I; Lymphocytes TCD 8 And 28
Citation: Gabriela Quintero, Jerzy Trojan., et al. “Glioblastoma - Application of Gene Therapy During A Quarter of A Century: Anti - Gene IGF-I Strategy”.Acta Scientific Cancer Biology 4.1 (2020): 38-45.
Copyright: © 2020 Gabriela Quintero, Jerzy Trojan.,et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.